Definitive Contract 75N91022C00021
Award Date 8/25/22
Potential Completion Date 9/14/23
Potential Value $399K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Worcester, MA 01605, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a $1,987,032 Firm Fixed Price SBIR Phase II contract awarded by the National Cancer Institute (NCI) to Spatial Surgical LLC, a for-profit limited liability company. The contract supports research and development of an integrated cell culture chamber and flow guide for point-of-care, walk-away operation of autologous T cell manufacturing, which aligns with NCI's public health mission. Spatial Surgical has also received other federal grants and contracts from agencies like the National...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Celartia, Inc., a small disadvantaged business, for the development of a fully automated system for cell therapy processing. The contract has a period of performance from September 13, 2021 to June 12, 2022 and a ceiling value of $393,312. The contract was awarded under a total small business set-aside. The original...
- This is a $399,062 firm-fixed-price SBIR Phase I contract awarded by the National Cancer Institute (NCI) to Avoneaux Medical Institute, LLC for the development of spatial micro-purification technology. The contract was set aside for small businesses and is part of the NCI's broader SBIR program, which funds research and development in support of the NIH and CDC's mission needs. The original solicitation sought proposals on a range of cancer-related topics, including alternatives to cell...
- This is a $1,997,803 firm fixed-price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to Cell Microsystems Inc., a small business manufacturer of specialized biomedical research equipment and tools. The contract is for the topic "Integrated Imaging and Molecular Analysis of Glioblastoma Using SCOPE SEQ on the Air Flow" and has a total small business set-aside designation. The contract will support...
- This is a Firm Fixed Price contract awarded by the National Institutes of Health (NIH) National Cancer Institute to Cell Microsystems Inc., a small business manufacturer of tools for imaging, sorting, and isolating single cells and colonies. The $2,295,432.00 contract, which is part of the Small Business Innovation Research (SBIR) program, supports the integration of Cell Microsystems' SCOPE SEQ technology with air flow capabilities for the molecular analysis of glioblastoma, an aggressive...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Lineage Cell Therapeutics, Inc. for the development of high content screening of 3D cultured cancer cells. The contract has a ceiling value of $285,423 and is a definitive, firm fixed-price contract with a completion date of September 4, 2014. The contract is set aside for small businesses. No other subcontractors are mentioned in the provided information.
- <p>This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), a civilian federal agency, to Transgenex Nanobiotech Inc., a minority-owned small business, for the development of a "fibrous scaffold-induced spheroids mimicking TME" solution. The contract, valued at $299,992.00, is a definitive, firm fixed-price contract with a completion date of July 21, 2014. The contract was set aside for the participation of small businesses.</p>
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Targagenix, Inc. for R&D on a nanoemulsion formulation and IND-enabling studies of a novel cancer stem cell cytotoxic agent. The definitive, firm-fixed-price contract has a ceiling value of $2,284,577.00 and a period of performance ending on October 15, 2018. As an SBIR Phase I award, this contract supports early-stage research and development...
- This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Neuralrad LLC, a small business, for $454,559.00. The contract was awarded under the SBIR (Small Business Innovation Research) program to support the development of "Quantitative Imaging Software Tools for Cancer Diagnosis and Treatment Planning" as described in the original solicitation. This Phase I SBIR contract has a period of performance from...
- <p>This is a $1,496,276.00 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a civilian agency, to Cellerant Therapeutics, Inc. The contract is for the SBIR (Small Business Innovation Research) Phase II development of novel therapeutic agents that target cancer stem cells, under Topic 326. The contract has a total small business set-aside designation and was awarded on September 19, 2016 with an ultimate completion date of April 16, 2018.</p>